RecruitingPhase 2NCT07303907

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder

Sponsor

Definium Therapeutics US, Inc.

Enrollment

20 participants

Start Date

Dec 3, 2025

Study Type

INTERVENTIONAL

Conditions

Autism Spectrum Disorder ASD

Summary

A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) for people with asd and autism spectrum disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA